Literature DB >> 11244010

Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III.

S S Franklin1, M J Jacobs, N D Wong, G J L'Italien, P Lapuerta.   

Abstract

The purpose of the present study was to examine patterns of systolic and diastolic hypertension by age in the nationally representative National Health and Nutrition Examination Survey (NHANES) III and to determine when treatment and control efforts should be recommended. Percentage distribution of 3 blood pressure subtypes (isolated systolic hypertension, combined systolic/diastolic hypertension, and isolated diastolic hypertension) was categorized for uncontrolled hypertension (untreated and inadequately treated) in 2 age groups (ages <50 and >/=50 years). Overall, isolated systolic hypertension was the most frequent subtype of uncontrolled hypertension (65%). Most subjects with hypertension (74%) were >/=50 years of age, and of this untreated older group, nearly all (94%) were accurately staged by systolic blood pressure alone, in contrast to subjects in the untreated younger group, who were best staged by diastolic blood pressure. Furthermore, most subjects (80%) in the older untreated and the inadequately treated groups had isolated systolic hypertension and required a greater reduction in systolic blood pressure than in the younger groups (-13.3 and -16.5 mm Hg versus -6.8 and -6.1 mm Hg, respectively; P:=0.0001) to attain a systolic blood pressure treatment goal of <140 mm Hg. Contrary to previous perceptions, isolated systolic hypertension was the majority subtype of uncontrolled hypertension in subjects of ages 50 to 59 years, comprised 87% frequency for subjects in the sixth decade of life, and required greater reduction in systolic blood pressure in these subjects to reach treatment goal compared with subjects in the younger group. Better awareness of this middle-aged and older high-risk group and more aggressive antihypertensive therapy are necessary to address this treatment gap.

Entities:  

Mesh:

Year:  2001        PMID: 11244010     DOI: 10.1161/01.hyp.37.3.869

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  193 in total

Review 1.  Systolic hypertension and cardiovascular risk reduction: a clinical review.

Authors:  W C Cushman
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

2.  Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.

Authors:  Joel Neutel; Dean J Kereiakes; Kathy A Stoakes; Jen-Fue Maa; Ali Shojaee; William F Waverczak
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 3.  Systolic pressure, diastolic pressure, or pulse pressure as a cardiovascular risk factor in renal disease.

Authors:  José A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

4.  Arteriosclerosis: A Primer for "In Focus" Reviews on Arterial Stiffness.

Authors:  Gary F Mitchell; Janet T Powell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-22       Impact factor: 8.311

Review 5.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

6.  Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension.

Authors:  P Hamet; E Merlo; O Seda; U Broeckel; J Tremblay; M Kaldunski; D Gaudet; G Bouchard; B Deslauriers; F Gagnon; G Antoniol; Z Pausová; M Labuda; M Jomphe; F Gossard; G Tremblay; R Kirova; P Tonellato; S N Orlov; J Pintos; J Platko; T J Hudson; J D Rioux; T A Kotchen; A W Cowley
Journal:  Am J Hum Genet       Date:  2005-03-30       Impact factor: 11.025

7.  Novel therapeutic strategies for reducing arterial stiffness.

Authors:  Carmel M McEniery
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 8.  Can we justify goal blood pressure of <140/90 mm Hg in most hypertensives?

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

9.  Aging, vascular risk, and cognition: blood glucose, pulse pressure, and cognitive performance in healthy adults.

Authors:  Cheryl L Dahle; Bradley S Jacobs; Naftali Raz
Journal:  Psychol Aging       Date:  2009-03

10.  The sex-specific impact of systolic hypertension and systolic blood pressure on arterial-ventricular coupling at rest and during exercise.

Authors:  Paul D Chantler; Vojtech Melenovsky; Steven P Schulman; Gary Gerstenblith; Lewis C Becker; Luigi Ferrucci; Jerome L Fleg; Edward G Lakatta; Samer S Najjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.